In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46. C ...

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations ...

Climb Bio Inc.’s stock-tickling event May 5 highlighting Fc-enhanced monoclonal antibody (mAb) budoprutug, followed two days later by a financial update, has kept Wall Street buzzing. Mizuho analyst ...

First quarter performance driven by strong year-over-year royalty revenue growth of 56%Reaffirms Previously Raised 2026 Full-Year Financial ...

Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao ...

RightCrowd today announced the RightCrowd Spoke on ServiceNow, its physical access integration for the ServiceNow AI platform. The integration automates the execution of physical access ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

"I’m attending so that I can be seen and heard,” said AKF Ambassador Ashli Littleton, who lives in Clarksville, Tennessee and is attending the Kidney Action Summit for the first time. "We have to be ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street ...